Inavolisib Plus Palbociclib–Fulvestrant Prolongs PFS in Patients with PIK3CA-mutated, HR-positive, HER2-negative Advanced Breast Cancer By Ogkologos - November 28, 2024 763 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the INAVO120 study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Granting a Marketing Authorisation for Poherdy Whole-Genome Sequencing Meets Diagnostic Requirements in Routine Practice for Patients with Solid Cancers FDA Approves Relacorilant with nab-Paclitaxel for Platinum-Resistant Epithelial Ovarian, Fallopian Tube, Or Primary Peritoneal Cancer MOST POPULAR ΚΑΡΚΙΝΟΣ ΤΟΥ ΠΝΕΥΜΟΝΑ:ΝΕΑ ΜΕΛΕΤΗ, ΝΕΕΣ ΕΛΠΙΔΕΣ December 27, 2018 Datopotamab Deruxtecan Shows Promising Activity in Heavily Pretreated Advanced HR-positive/HER2-negative and... May 7, 2024 FDA Grants Accelerated Approval to Tucatinib with Trastuzumab for Colorectal Cancer January 25, 2023 The First Report from the Cancer Programme of the 100,000 Genomes... January 16, 2024 Load more HOT NEWS Telehealth-Based Cancer Care Surged during COVID. Will It Continue? ΚΑΡΚΙΝΟΣ ΤΟΥ ΜΑΣΤΟΥ Pazopanib Is Not Inferior to Doxorubicin in First-Line Treatment of Elderly... Cancer in My Community: Working to Eliminate the Stigma of Cancer...
